- In March 2025, the University of California, San Francisco (UCSF) initiated a Phase 2 clinical trial to evaluate the combination of Belimumab and Rituximab for the treatment of primary membranous nephropathy. This groundbreaking study aims to explore whether dual B-cell inhibition can improve disease remission rates and reduce relapse in comparison to monotherapy. The trial underscores UCSF’s leadership in nephrology research and highlights the growing shift toward biologic combination therapies for complex kidney diseases in the U.S.
- In February 2025, BeiGene USA Inc. announced the launch of a Phase 2 trial to assess the safety and efficacy of Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy. This study marks one of the first applications of BTK inhibitors in autoimmune kidney disorders, showcasing the potential for targeted immunomodulation in nephrology. The move represents BeiGene’s expanding U.S. research footprint and innovation in kidney disease therapeutics
